# The Mechanism of Action of Stigmasterol in Bone Formation in Osteoporosis

**Authors:** Cailian Lu, Hong Li, Zhengbo Liu, Sirui Lü, Junxing Liu

PMC · DOI: 10.3390/cimb48030337 · 2026-03-23

## TL;DR

Stigmasterol improves bone formation in osteoporosis by activating a key signaling pathway that enhances osteoblast differentiation.

## Contribution

This study identifies the JAK2/STAT3 pathway as a novel mechanism through which stigmasterol promotes osteogenic differentiation and bone protection.

## Key findings

- Stigmasterol improved bone microarchitecture in ovariectomized rats and increased osteogenic marker expression.
- Stigmasterol promoted osteogenic differentiation of MC3T3-E1 cells in a dose-dependent manner.
- Network pharmacology and mechanistic studies revealed JAK2/STAT3 activation as the key pathway involved in stigmasterol's effects.

## Abstract

Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone mass and impaired bone microarchitecture, significantly impacting patients’ quality of life. Stigmasterol (STG), a natural plant sterol, has been reported to possess multiple biological activities. However, its effects on OP bone formation and underlying molecular mechanisms remain unclear. The effects of STG on OP bone formation and potential mechanisms were investigated through in vivo and in vitro experiments combined with network pharmacology analysis. An OP model was established in ovariectomized (OVX) rats, and the bone-protective effects of STG were evaluated via micro-CT analysis and histological staining. In vitro experiments, MC3T3-E1 pre-osteoblasts were used to assess STG’s influence on osteogenic differentiation through Western blot analysis and ALP/ARS staining. Network pharmacology methods were used to predict potential targets and signaling pathways for STG in OP treatment, followed by mechanism validation. STG significantly improved bone microarchitecture in OVX rats, increased key osteogenic marker expression, and promoted MC3T3-E1 osteogenic differentiation in a dose-dependent manner. Network pharmacology analysis predicted 278 potential targets for STG in treating OP, with pathway enrichment analysis indicating significant involvement of the JAK/STAT pathway. Mechanistic studies revealed that STG promotes osteogenic differentiation by activating the JAK2/STAT3 signaling cascade. As an osteogenic promoter, STG effectively alleviates bone loss and enhances osteoblast differentiation by activating the JAK2/STAT3 signaling pathway.

## Linked entities

- **Proteins:** JAK2 (Janus kinase 2), STAT3 (signal transducer and activator of transcription 3)
- **Chemicals:** Stigmasterol (PubChem CID 5280794), STG (PubChem CID 136344513)
- **Diseases:** Osteoporosis (MONDO:0005298)
- **Species:** Rattus norvegicus (taxon 10116), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Sp7 (Sp7 transcription factor) [NCBI Gene 300260] {aka Osx}, 2300002M23Rik (RIKEN cDNA 2300002M23 gene) [NCBI Gene 69542] {aka Stg, emprin}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Esr1 (estrogen receptor 1 (alpha)) [NCBI Gene 13982] {aka ER, ER-alpha, ERa, ERalpha, ESR, Estr}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, Jak2 (Janus kinase 2) [NCBI Gene 24514], Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Sp7 (Sp7 transcription factor 7) [NCBI Gene 170574] {aka 6430578P22Rik, C22, Osx}, Hif1a (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 29560] {aka HIF1-alpha, MOP1}, Pdlim3 (PDZ and LIM domain 3) [NCBI Gene 114108] {aka Actn2lp, Alp}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Runx2 (RUNX family transcription factor 2) [NCBI Gene 367218] {aka CBF-alpha-1, Cbfa1, OSF-2}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}, Actb (actin, beta) [NCBI Gene 81822] {aka Actx}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, alp (alopecia, recessive) [NCBI Gene 11691], Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Bglap (bone gamma-carboxyglutamate protein) [NCBI Gene 25295] {aka Bglap2, Bgp, Bgpr, Bgpra}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Egf (epidermal growth factor) [NCBI Gene 13645], Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Cyp19a1 (cytochrome P450, family 19, subfamily a, polypeptide 1) [NCBI Gene 25147] {aka Aromatase, Cyp19, Cyp19a, p450arom}, Slurp1 (secreted Ly6/Plaur domain containing 1) [NCBI Gene 57277] {aka 1110021N19Rik, ARS, ArsB, Slurp-1}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Ghr (growth hormone receptor) [NCBI Gene 25235] {aka GHR/BP}
- **Diseases:** arthritis (MESH:D001168), cytotoxic (MESH:D064420), osteoarthritis (MESH:D010003), osteonecrosis of the jaw (MESH:D059266), infection (MESH:D007239), injury to (MESH:D014947), Bone (MESH:D001847), Osteoporotic (MESH:D058866), skeletal diseases (MESH:D004194), skeletal disorder (MESH:C564967), OP (MESH:D010024), traumatic fractures (MESH:D050723), inflammatory (MESH:D007249), esophagitis (MESH:D004941), estrogen deficiency (MESH:D056828), overdose (MESH:D062787), CIA (MESH:D001169)
- **Chemicals:** vegetable oils (MESH:D010938), paraformaldehyde (MESH:C003043), eosin (MESH:D004801), DAPI (MESH:C007293), SDS (MESH:D012967), xylene (MESH:D014992), genistein (MESH:D019833), EDTA (MESH:D004492), benzene (MESH:D001554), cholesterol (MESH:D002784), BCIP (-), bisphosphonates (MESH:D004164), pyridine (MESH:C023666), hydrogen (MESH:D006859), PVDF (MESH:C024865), EDU (MESH:C022811), chloroform (MESH:D002725), ethanol (MESH:D000431), crystal violet (MESH:D005840), Triton X-100 (MESH:D017830), AG490 (MESH:C095512), acetone (MESH:D000096), pentobarbital sodium (MESH:D010424), plant sterols (MESH:D010840), Tween-80 (MESH:D011136), CO2 (MESH:D002245), Hematoxylin (MESH:D006416), STG (MESH:D013265), PEG300 (MESH:C000595211), Fedratinib (MESH:C528327), N (MESH:D009584), water (MESH:D014867), sterol (MESH:D013261), Alizarin Red (MESH:C010078), E2 (MESH:D004958), paraffin (MESH:D010232), formalin (MESH:D005557), ethyl acetate (MESH:C007650), PBS (MESH:D007854), Penicillin (MESH:D010406), H&amp;E (MESH:D006371)
- **Species:** Homo sapiens (human, species) [taxon 9606], Brassica napus var. napus (annual rape, varietas) [taxon 138011], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** MC3T3-E1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0409), vascular smooth muscle — Homo sapiens (Human), Finite cell line (CVCL_4009)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025589/full.md

---
Source: https://tomesphere.com/paper/PMC13025589